Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090916 · ClinicalTrials.gov registry record · NA
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
A NA study of Stage III Pancreatic Cancer and Pancreatic Adenocarcinoma Non-resectable, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06090916: Active NA study of Stage III Pancreatic Cancer and Pancreatic Adenocarcinoma Non-resectable, sponsored by Jonsson Comprehensive Cancer Center.
NCT06090916 is a NA study of Stage III Pancreatic Cancer and Pancreatic Adenocarcinoma Non-resectable that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 100 participants, below the 159-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090916, a NA study of Stage III Pancreatic Cancer and Pancreatic Adenocarcinoma Non-resectable, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable). Fewer than 20% of patients diagnosed with unresectable pancreatic cancer do not survive one year after diagnosis so treatment often focuses on improving quality of life. Many patients experience increasing pain, nausea, vomiting, loss of appetite, weight loss and weakness. Behavioral interventions use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. Screening for inadequate nutrition (malnutrition) and providing weekly nutritional support may be effective methods to improve nutritional status and improve overall quality of life for patients with unresectable pancreatic cancer.
Primary Outcome
Measured using short form 36. A two-sample t-test comparing changes from baseline in each of the outcomes between study arms used to estimate power
Conditions Studied
Interventions
- OTHER Medical Device Usage and Evaluation
- OTHER Medical Chart Review
- OTHER Best Practice
- OTHER Dietary Intervention
- OTHER Nutritional Assessment
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What the registry record for NCT06090916 still lists
NCT06090916 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 159-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Stage III Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Medical Device Usage and Evaluation is the first listed.
NCT06090916 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06090916 about?
NCT06090916 is a clinical study titled "Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer". This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable). Fewer than 20% of patients diagnosed with unresectable pancreatic cancer do not survive one year ...
What is the current status of trial NCT06090916?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-01-17. Estimated completion is 2027-03-31.
What conditions does trial NCT06090916 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma Non-resectable.
What interventions are being tested in trial NCT06090916?
The interventions under investigation include: Medical Device Usage and Evaluation (OTHER), Medical Chart Review (OTHER), Best Practice (OTHER), Dietary Intervention (OTHER), Nutritional Assessment (OTHER).
Who is sponsoring clinical trial NCT06090916?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090916 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06090916's enrollment target sits among peer trials
100 5th of 13 higher than 9 of 13 other Stage III Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
ACTIVE NOT RECRUITING
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI